Patient Support

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.

Why meaningful content must meet the right audience.

The presidential action follows up on a 2019 final rule aimed at empowering patients and boosting competition among hospitals, group health plans, and health insurance issuers in both individual and group markets.

Patients who utilize the self-pay pharmacy will also be receiving savings on select sizes.

James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction in cost and increase in patient access, while highlighting challenges to adoption.

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

A qualitative study examines how Medicaid telehealth reimbursement policies affect staffing and patient-centered care.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, describes why these pharma supply chain stakeholders are vital in understanding meaningful clinical outcomes.

Digging a little deeper into the drug class phenomenon reveals some interesting takeaways on a smaller subgroup of users.

The agreement is centered around improving cell culture efficiency and CGT quality.

How chain and local closures are impacting healthcare access.

From matrix programs to anti-abandonment strategies, predictions for a new era.

A cohort study investigates the magnitude of lost coverage among pediatric patients, following the conclusion of the pandemic public health emergency.

New engagement approaches can help drive treatment gains in underrepresented communities.

A survey study of US employers aims to determine whether they prioritize financial or nonfinancial criteria when selecting health plans.

A report offers a comprehensive benchmarking and assessment of pharmaceutical manufacturer engagement with specialty pharmacies.

Can monitoring these dispensed Rxs via online search behavior help predict future GLP-1 use in the United States?

A study explores dual-enrollment in these plans—compared to other Medicare Advantage plans— impacts North Carolina’s Medicaid fee-for-service spending.

The investment not only moves along the company’s efforts in advancing clinical studies, but also opens up 700 new jobs for the Greater Toronto area.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, describes the importance of the patient within the pharma supply chain.

The latest AARP report concludes that plan members who hit this amount are expected to see savings, even when premiums are considered.

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, discusses the origins of the compounding pharmacy, including what it seeks to accomplish.

Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.

These medications are used to treat a multitude of conditions including type 2 diabetes, cancer and asthma.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, describes compounding pharmacies’ efforts in tackling the tirzepatide shortage, and dispels the notion that commercialized and compounded drugs are competing with one another.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, comments on the role that compounding pharmacies play in the pharmaceutical supply chain from a macro perspective.

Cryoport's business unit, Cryogene, will be tasked with helping to foster the growth of Moffitt’s cell and gene therapy efforts.

The collaboration is powered by the discovery and development of obesity, type 2 diabetes, and cardiovascular disease treatments.

The new form of the vaccine would remove the need for HCPs to combine the powder antigen and liquid adjuvant themselves prior to administering.